TrialHealth and quality of life outcomes2019

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.

Marco Montillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.